A minimal common outcome measure set for COVID-19 clinical researchJohn C. Marshall, Halima Salisu-Kabara, Scott Berry et al.|The Lancet Infectious Diseases|2020Cited by 1.8k
Increased Risk for Malignancies in 131 Affected CTLA4 Mutation CarriersDavid Egg, Bodo Grimbacher, Charlotte Schwab et al.|Frontiers in Immunology|2018Cited by 103
A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory TractFrancisco M. Marty, Sanjeet Dadwal, Roy F. Chemaly et al.|Clinical Infectious Diseases|2019Cited by 76
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant RecipientsRoy F. Chemaly, Michael Boeckh, Sanjeet Dadwal et al.|Clinical Infectious Diseases|2019Cited by 75